BioArctic receives European patent for new antibodies targeting Alzheimer’s disease
The Pharma Data
JANUARY 26, 2021
27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. STOCKHOLM , Jan. About BioArctic AB.
Let's personalize your content